Structure Therapeutics (NASDAQ:GPCR) Shares Up 3.7% – Time to Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR) shares traded up 3.7% during mid-day trading on Tuesday . The stock traded as high as $41.97 and last traded at $41.87. 73,894 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 783,387 shares. The stock had previously closed at $40.38.

Analyst Ratings Changes

GPCR has been the topic of a number of recent analyst reports. Morgan Stanley began coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, JMP Securities cut their price objective on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $87.83.

Structure Therapeutics Stock Performance

The firm’s 50 day moving average price is $38.73 and its two-hundred day moving average price is $40.10. The firm has a market cap of $1.93 billion, a PE ratio of -53.82 and a beta of -3.53.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. On average, analysts forecast that Structure Therapeutics Inc. will post -0.86 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GPCR. Avoro Capital Advisors LLC grew its stake in shares of Structure Therapeutics by 133.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after acquiring an additional 1,333,333 shares in the last quarter. Braidwell LP acquired a new stake in Structure Therapeutics in the 4th quarter valued at about $11,419,000. ADAR1 Capital Management LLC acquired a new position in shares of Structure Therapeutics during the fourth quarter worth about $163,000. Boxer Capital LLC acquired a new position in shares of Structure Therapeutics during the fourth quarter worth about $16,304,000. Finally, Brandywine Managers LLC increased its stake in shares of Structure Therapeutics by 9.2% during the fourth quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after buying an additional 1,007 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.